



Radiochemotherapy, Radioimmunotherapy and Targeted Therapy in Locally Advanced and Metastatic Head and Neck Cancer

Guest Editor:

Dr. Lianghao Ding

Department of Radiation
Oncology, UT Southwestern
Medical Center, Dallas, TX, USA

Deadline for manuscript
submissions:

20 September 2024

Message from the Guest Editor

Dear Colleagues,

Locally advanced head and neck cancer presents complex challenges for cancer management and significantly affects the overall survival rates of patients. Radiochemotherapy is the standard treatment modality for this type of cancer, either as a post-surgery adjuvant therapy or definitive therapy for non-operable tumors. In this Special Issue, we will examine the latest advancements in clinical research, cancer biology and precision medicine, all with the goal of achieving improved tumor eradication and minimizing toxicities associated with radiochemotherapy. We will also review the progress of targeted therapy and emerging immunotherapy with checkpoint inhibitors, particularly when used in combination with radiotherapy.

Dr. Lianghao Ding
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)